Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
OtherBasic Science (Animal or Phantoms)

Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose 211At-Labeled Anti-HER2 Single Domain Antibody Fragment

Yutian Feng, Rebecca Meshaw, Xiao-guang Zhao, Stephen A. Jannetti, Ganesan Vaidyanathan and Michael R. Zalutsky
Journal of Nuclear Medicine May 2022, jnumed.122.264071; DOI: https://doi.org/10.2967/jnumed.122.264071
Yutian Feng
Duke University Medical Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca Meshaw
Duke University Medical Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiao-guang Zhao
Duke University Medical Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen A. Jannetti III
Duke University Medical Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ganesan Vaidyanathan
Duke University Medical Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael R. Zalutsky
Duke University Medical Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael R. Zalutsky
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Abstract

Single-domain antibody fragments (sdAbs) are attractive for targeted α-particle therapy (TAT), particularly with 211At, because of their rapid accumulation in tumor and clearance from normal tissues. Here, we evaluate the therapeutic potential of this strategy with 5F7 and VHH_1028 - two sdAbs that bind with high affinity to Domain IV of human epidermal growth factor receptor type 2 (HER2). Methods: The HER2-specific sdAbs and HER2-irrelevant VHH_2001 were labeled using N-succinimidyl 3-[211At]astato-5-guanidinomethyl benzoate (iso-[211At]SAGMB). The cytotoxicity of iso-[211At]SAGMB-5F7 and iso-[211At]SAGMB-VHH_2001 were compared on HER2-expressing BT474 breast carcinoma cells. Three experiments in mice with subcutaneous BT474 xenografts were performed to evaluate the therapeutic effectiveness of single doses of 1) iso-[211At]SAGMB-5F7 (0.7-3.0 MBq), 2) iso-[211At]SAGMB-VHH_1028 (1.0-3.0 MBq), and 3) iso-[211At]SAGMB-VHH_1028 and iso-[211At]SAGMB-VHH_2001 (~1.0 MBq). Results: Clonogenic survival of BT474 cells was reduced after exposure to iso-[211At]SAGMB-5F7 (D0=1.313 kBq/mL) while iso-[211At]SAGMB-VHH_2001 was ineffective. Dose-dependent tumor growth inhibition was observed with 211At-labeled HER2-specific 5F7 and VHH_1028 but not with HER2-irrelevant VHH_2001. At the 3.0 MBq dose, complete tumor regression was seen in 3 of 4 mice treated with iso-[211At]SAGMB-5F7 and 8 of 11 mice treated with iso-[211At]SAGMB-VHH_1028; prolongation in median survival was 495% and 414%, respectively. Conclusion: Combining rapidly internalizing, high-affinity HER2-targeted sdAbs with the iso-[211At]SAGMB residualizing prosthetic agent is a promising strategy for TAT of HER2-expressing cancers.

  • Oncology: Breast
  • Radiochemistry
  • Radionuclide Therapy
  • &[alpha]-emtter
  • HER2
  • nanobody
  • radiopharmaceutical therapy
  • single-domain antibody fragment
  • Copyright © 2022 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 64 (9)
Journal of Nuclear Medicine
Vol. 64, Issue 9
September 1, 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose 211At-Labeled Anti-HER2 Single Domain Antibody Fragment
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose 211At-Labeled Anti-HER2 Single Domain Antibody Fragment
Yutian Feng, Rebecca Meshaw, Xiao-guang Zhao, Stephen A. Jannetti, Ganesan Vaidyanathan, Michael R. Zalutsky
Journal of Nuclear Medicine May 2022, jnumed.122.264071; DOI: 10.2967/jnumed.122.264071

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose 211At-Labeled Anti-HER2 Single Domain Antibody Fragment
Yutian Feng, Rebecca Meshaw, Xiao-guang Zhao, Stephen A. Jannetti, Ganesan Vaidyanathan, Michael R. Zalutsky
Journal of Nuclear Medicine May 2022, jnumed.122.264071; DOI: 10.2967/jnumed.122.264071
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Keywords

  • Oncology: Breast
  • Radiochemistry
  • Radionuclide Therapy
  • &[alpha]-emtter
  • HER2
  • Nanobody
  • radiopharmaceutical therapy
  • single-domain antibody fragment
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire